List view / Grid view
24 September 2015 | By Victoria White
Sayana Press combines a long-acting, reversible, contraceptive with an all-in-one prefilled, single-use, non-reusable Uniject injection system...
24 September 2015 | By Victoria White
Fexeric is approved for the control of elevated serum phosphorus levels in adults with chronic kidney disease, including both dialysis and pre-dialysis patients...
24 September 2015 | By
The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million euros...
24 September 2015 | By Victoria White
Idelalisib has been recommended in combination with rituximab for adults with chronic lymphocytic leukaemia (CLL) who have relapsed early...
24 September 2015 | By Victoria White
ABP 215 is being developed as a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb)...
23 September 2015 | By Victoria White
NICE has issued its final recommendation for edoxaban to help prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation...
23 September 2015 | By Victoria White
In a Phase III study, significantly more patients who received Esbriet showed delayed progression of idiopathic pulmonary fibrosis (IPF) than those who received placebo...
23 September 2015 | By Victoria White
A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy...
23 September 2015 | By Victoria White
Turing, the company that increased the price of Daraprim by over 5000%, has said that the price of the drug will be lowered but has not confirmed what the new price will be...
23 September 2015 | By Victoria White
This year’s entries include innovations and new service offerings from across the entire spectrum of the pharmaceutical supply chain...
23 September 2015 | By Victoria White
The Company said that the clinical data from a Phase 1/2a study confirm the very good overall safety profile of the fully human HuCAL antibody...
22 September 2015 | By Victoria White
Zalviso is designed to offer sustained (for up to 72 hours) pain relief for acute moderate-to-severe post-operative pain...
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
22 September 2015 | By Victoria White
The FDA awards the grants through the Orphan Products Grants Programme to encourage clinical development of treatments for use in rare diseases...
22 September 2015 | By Victoria White
Both Phase 3 studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo...
